ASH 2022 | The use of NGS in the diagnosis and treatment of Richter’s transformation
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, discusses how the advent of next-generation sequencing (NGS) may help with the diagnosis and treatment of Richter’s transformation (RT). Dr Kipps explains that patients can develop either clonally-related RT or de novo RT, which behaves more like diffuse large B-cell lymphoma (DLBCL), and highlights that understanding the genetic changes that are associated with Richter’s transformations is important, as it may facilitate diagnoses, clinical decisions, and guide the development of novel agents targeting signaling pathways. Following this, Dr Kipps highlights that the ROR1 signaling pathway may be an attractive target for treatment, as it is known to have an important role in cell proliferation during embryogenesis and is overexpressed in leukemic cells. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie: Consultancy, Research Funding; Genentech-Roch: Consultancy, Research Funding; Gilead: Consultancy; Pharmacyclics, LLC an AbbVie Company: Consultancy, Research Funding; Celgene: Consultancy; Oncternal: Research Funding.
